key: cord-0804610-f2w2z7k5
authors: Hu, Yanmei; Ma, Chunlong; Szeto, Tommy; Hurst, Brett; Tarbet, Bart; Wang, Jun
title: Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Coronaviruses
date: 2021-03-01
journal: ACS Infect Dis
DOI: 10.1021/acsinfecdis.0c00761
sha: 96dc0061cc521891f0a5e9e49aa9ebed43bfad58
doc_id: 804610
cord_uid: f2w2z7k5

[Image: see text] As the COVID-19 pandemic continues to unfold, the morbidity and mortality are increasing daily. Effective treatment for SARS-CoV-2 is urgently needed. We recently discovered four SARS-CoV-2 main protease (M(pro)) inhibitors including boceprevir, calpain inhibitors II and XII, and GC-376 with potent antiviral activity against infectious SARS-CoV-2 in cell culture. In this study, we further characterized the mechanism of action of these four compounds using the SARS-CoV-2 pseudovirus neutralization assay. It was found that GC-376 and calpain inhibitors II and XII have a dual mechanism of action by inhibiting both viral M(pro) and host cathepsin L in Vero cells. To rule out the cell-type dependent effect, the antiviral activity of these four compounds against SARS-CoV-2 was also confirmed in type 2 transmembrane serine protease-expressing Caco-2 cells using the viral yield reduction assay. In addition, we found that these four compounds have broad-spectrum antiviral activity in inhibiting not only SARS-CoV-2 but also SARS-CoV, and MERS-CoV, as well as human coronaviruses (CoVs) 229E, OC43, and NL63. The mechanism of action is through targeting the viral M(pro), which was supported by the thermal shift-binding assay and enzymatic fluorescence resonance energy transfer assay. We further showed that these four compounds have additive antiviral effect when combined with remdesivir. Altogether, these results suggest that boceprevir, calpain inhibitors II and XII, and GC-376 might be promising starting points for further development against existing human coronaviruses as well as future emerging CoVs.

Coronaviruses (CoVs) are enveloped positive-stranded RNA virus that infect humans and multiple species of animals, causing a variety of highly prevalent and severe diseases. 1 In the last two decades, three highly pathogenic and lethal human coronaviruses have emerged: severe acute respiratory syndrome coronavirus (SARS-CoV), the virus that caused the outbreak of severe acute respiratory syndrome in humans in Southern China in 2002 and killed 774 people among 8098 infected worldwide; 2 MERS-CoV, which caused severe respiratory disease outbreak in Middle East in 2012 and led to 791 deaths among 2229 infected; 3 the SARS-CoV-2, a novel coronavirus which emerged in China in December 2019, quickly spread worldwide, and became a global pandemic. 4 As of February 17, 2021, there have been more than 109 million confirmed cases and over 2.4 million deaths worldwide, and these numbers are increasing daily (https://coronavirus.jhu. edu/map.html). In addition, human coronavirus (HCoV) strains 229E (HCoV-229E), NL63 (HCoV-NL63), OC43 (HCoV-OC43), and HKU1 (HCoV-HKU1) cause a significant portion of the annual upper and lower respiratory tract infections in humans, including common colds, bronchiolitis, and pneumonia. 5−7 The current COVID-19 pandemic is a timely reminder of the urgent need for therapeutics against coronavirus infection. As future coronavirus outbreak cannot be excluded, broad-spectrum antivirals are desired to combat not only existing CoVs but also future emerging CoVs.

The coronavirus genome ranges from 26 to 32 kb, of which the 3′-terminal region, approximately one-third of the genome, encodes a number of structural proteins (spike protein, envelope protein, membrane protein, and nucleocapsid protein), while the 5′-terminal region, approximately twothirds of the genome, encodes for the nonstructural proteins (3-chymotrypsin-like protease (3CL or main protease), papain-like protease, helicase, RNA-dependent RNA polymerase, exoribonuclease and endoribonuclease, methyl transferase), and accessary proteins. 8 Among the viral proteins under investigation as antiviral drug targets, the main protease (M pro ) appears to be a high-profile drug target for development of broad-spectrum antivirals for the following reasons: (1) M pro plays an essential role in coronavirus replication by cleaving the viral polyproteins at more than 11 sites; 9 (2) M pro s have relatively high sequence similarity within each CoV group; 10 (3) M pro has an unique substrate preference for glutamine at the P1 site (Leu-Gln↓(Ser, Ala, Gly)), a feature that is absent in closely related host proteases, 11 suggesting it is feasible to design M pro inhibitors with a high selectivity; (4) the structures of M pro s from multiple members of the CoV family have been solved, 12−15 paving the way for rational drug design.

We recently discovered four SARS-CoV-2 M pro inhibitors including boceprevir, calpain inhibitors II and XII, and GC-376 ( Figure 1 ). 16 They had single-digit micromolar to submicromolar IC 50 values in the enzymatic assay and inhibited SARS-CoV-2 viral replication in Vero cells with EC 50 values in the single-digit micromolar to submicromolar range. 16 The cocrystal structures of GC-376, calpain inhibitors II and XII in complex with SARS-CoV-2 M pro have been solved, providing a molecular explanation for the tight binding of these compounds toward M pro . 16 , 17 We also found calpain inhibitors II and XII inhibit human cathepsin L in the in vitro enzymatic assay, 17 and cathepsin L has been shown to play an essential role in SARS-CoV-2 cell entry by activating the viral spike protein in the late endosome or lysosome. 18, 19 A recent study also discovered that GC-373, the active form of GC-376, similarly inhibited the enzymatic activity of cathepsin L with an IC 50 of 4.0 nM and showed cell-type dependent inhibition against SARS-CoV-2. 20 These observations led us to speculate that the cellular antiviral activity of calpain inhibitors II and XII, and GC-376 in Vero cells might be a result of inhibiting both viral M pro and host cathepsin L. To test this hypothesis, we performed SARS-CoV-2 pseudovirus neutralization assay, and the results supported the contribution of inhibition of cathepsin L to the cellular antiviral activity of GC-376, and calpain inhibitors II and XII against SARS-CoV-2 in Vero cells.

SARS-CoV-2 enters the cell through two different pathways, either the type 2 transmembrane serine protease (TMPRSS2) mediated direct cell membrane fusion or endocytosis. 18, 19 In the endocytosis pathway, endosome associated cathepsin L mediated the cleavage of viral spike protein and cathepsin L inhibitors have been shown to inhibit SARS-CoV-2 and SARS-CoV replication in cell culture. 18, 19 However, the inhibition is cell-type dependent, and the antiviral activity is decreased or abolished in cells expressing TMRPSS2 that does not rely on endocytosis for viral entry. 18−20 To rule out the cell type dependent inhibition of these four compounds against SARS-CoV-2, we performed viral yield reduction (VYR) assay in Caco-2 cells, which expresses TMPRSS2 and is a physiological relevant cell culture model for SARS-CoV-2 replication, 19, 21, 22 and found that all four compounds had potent antiviral activity.

To evaluate the broad-spectrum antiviral activity of boceprevir, calpain inhibitors II and XII, and GC-376, we tested them against two other highly pathogenic coronaviruses, SARS-CoV and MERS-CoV, as well as three human coronaviruses HCoV-OC43, HCoV-NL63, and HCoV-229E. The mechanism of action was studied by the thermal shiftbinding assay and fluorescence resonance energy transfer (FRET) based enzymatic assay. The combination therapy potential of these four compounds with remdesivir was also quantified by the drug combination index method. Altogether, our work demonstrated that boceprevir, calpain inhibitors II and XII, and GC-376 might be promising starting points for the design and development of broad-spectrum antivirals against current and future emerging CoVs.

Calpain Inhibitors II and XII and GC-376, but Not Boceprevir, Inhibited SARS-CoV-2 Pseudovirus Neutralization in Vero Cells. Pseudovirus neutralization assay is an established model to study the mechanism of viral cell entry and has been widely used to assess the antiviral activity of viral entry/fusion and protease inhibitors. 23−25 Calpain inhibitors II and XII are potent inhibitors of human cathepsin L, with K I and IC 50 values in the nanomolar range. 17, 26 Surprisingly, GC-376 was also shown to inhibit cathepsin L with an IC 50 in the single-digit nanomolar range. 20 Cathepsin L plays an important role in SARS-CoV-2 viral entry by cleaving the viral spike S protein in the endosome or lysosome. 18, 19 We therefore hypothesized that the cellular antiviral mechanism of calpain inhibitors II and XII and GC-376 in Vero cells might involve inhibition of cathepsin L besides M pro . To test this hypothesis, we first generated SARS-CoV-2 pseudoviral particles in ACE2expressing HEK293T cells (ACE2/293T) as previously described. 23 We then performed pseudovirus entry assay in Vero E6 cells, which have minimal levels of TMPRSS2 expression. As such, SARS-CoV-2 cell entry is mediated through endocytosis, which mainly relies on cathepsin L for viral spike protein activation. 18 E-64d, a known cathepsin L inhibitor, was included as a positive control. As Vero cells have high levels of efflux transporter P-glycoprotein (P-gp), which is also known as MDR1 and ABCB1, 27 the pseudovirus assay was performed with and without CP-100356, a P-gp efflux inhibitor. The purpose is to differentiate the effect of drug efflux from cathepsin L inhibition. It was found that the positive control E-64d was not a substrate of P-gp and inhibited SARS-CoV-2 pseudovirus entry in the presence or absence of CP-1000356 with similar potency (Figure 2A ). The negative control, camostat, which is a TMPRSS2 inhibitor, did not inhibit SARS-CoV-2 pseudovirus entry with or without CP-100356 ( Figure 2B ). GC-376 did not inhibit SARS-CoV-2 pseudovirus entry in the absence of CP-100356 (IC 50 > 50 μM) ( Figure 2C black curve), contradictory to its potent inhibition of cathepsin L in the enzymatic assay as reported before. 20 It was known that the Pfizer clinical candidate PF-00835231 is a substrate of P-gp. 28 Given the structural similarity between PF-00835231 and GC-376, we hypothesized that GC-376 might also be a substrate of P-gp, and the lack of inhibition of GC-376 against the SARS-CoV-2 pseudovirus entry in Vero cells might be a result of drug efflux. Consistent with our hypothesis, it was found that GC-376 had potent inhibition of SARS-CoV-2 pseudovirus entry in the presence of CP-100356 with an IC 50 of 1.07 ± 0.24 μM ( Figure 2C Figure 2G ). Consistent with previously enzymatic assay results as well as our SARS-CoV-2 pseudovirus neutralization assay results, calpain inhibitors II and XII and GC-376 had potent inhibition against cathepsin L with IC 50 s ranging from 0.30 to 1.63 nM, similar to the positive control E-64 (IC 50 = 5.45 nM), and boceprevir had weak inhibition with an IC 50 of 153 nM. Altogether, it can be concluded that the cellular antiviral activity of GC-376, and calpain inhibitors II and XII in Vero cells involves the inhibition of cathepsin L, while boceprevir had little or no effect on cathepsin L-mediated viral entry. Our results also point out that the SARS-CoV-2 pseudovirus assay is a useful tool to evaluate the effect of drug candidates on the inhibition of cathepsin L as well as other host proteases that are involved in SARS-CoV-2 cell entry. With the P-gp inhibitor CP-100356, this assay can also identify compounds that might be P-gp substrates. GC-376, Calpain Inhibitors II and XII, and Boceprevir Inhibited SARS-CoV-2 Replication in Caco-2 Cells Using Viral Yield Reduction (VYR) Assay. Given the dual inhibition mechanism of GC-376 and calpain inhibitors II and XII in inhibiting both cathepsin L and M pro , it raised a potential concern of the potential cell type dependent inhibition for these compounds. As such, we further evaluated the antiviral potency of these four compounds against SARS-CoV-2 in Caco-2 cells. Caco-2 is a human colorectal adenocarcinoma cell line and has been shown to support the replication of SARS-CoV-2 at a similar level as the Calu-3 cell. 29−31 The Caco-2 cell line expresses TMPRSS2 and ACE2, 19, 21, 22 rendering it a physiologically relevant model for testing antiviral drug candidates. Using the viral yield reduction assay in Caco-2 cells, it was found that all four compounds GC-376, calpain inhibitors II and XII, and boceprevir inhibited SARS-CoV-2 replication with EC 50 values of 2.58 ± 0.21, 6.37 ± 0.73, 4.21 ± 1.45, and 2.97 ± 1.56 μM, respectively ( Figure  3 ). All four compounds were not toxic in Caco-2 cells (CC 50 > 100 μM).

The potent antiviral activity of these three compounds against SARS-CoV-2 in Caco-2 cells suggest that although GC-376 and calpain inhibitors II and XII inhibit both host cathepsin L and viral M pro in the in vitro enzymatic assay, cathepsin L inhibition appears to be dispensable and not essential for the antiviral activity, and M pro inhibition might be the driving factor for their cellular antiviral activity. Nevertheless, we cannot rule out the possibility that these compounds might also inhibit other host proteases that are involved in viral replication.

Boceprevir, Calpain Inhibitors II and XII, and GC-376 Bind to MERS-CoV, SARS-CoV, and HCoV-OC43 M pro . First, we performed sequence alignment of M pro from multiple members of coronavirus family: HCoV-229E, HCoV-OC43, HCoV-NL63, SARS-CoV, MERS-CoV, and SARS-CoV-2 ( Figure S1 ). Overall, the M pro s showed moderate to high similarity in primary sequence and comparatively high sequence similarity within each CoV group ( Figure S1 ). It is acknowledged that 3D structures of the M pro s are more conserved, especially at the active site. 32 Therefore, we hypothesized that boceprevir, calpain inhibitors II and XII, and GC-376 might similarly bind to other CoV M pro s in addition to SARS-CoV-2 M pro . To test this hypothesis, we carried out differential scanning fluorimetry (DSF) assay. 33 Specific binding of a ligand to a protein typically stabilizes the target protein, resulting in an increased melting temperature (T m ). It was found that boceprevir, calpain inhibitors II and XII, and GC-376 increased the T m of SARS-CoV, MERS-CoV, and HCoV-OC43 M pro in a dose dependent manner ( Figure  4) , while remdesivir had no effect on HCoV-OC43 M pro stability at up to 200 μM. This was expected as remdesivir is a known RNA-dependent RNA polymerase (RdRp) inhibitor. 34 (Figure 5D , E). When the proteolytic progression curves were fitted using the same two-step reaction mechanism, accurate values for the second rate constant k 2 could not be obtained for calpain inhibitors II and XII against all three M pro s as well as boceprevir against SARS-CoV and HCoV-OC43 M pro s. This is presumably due to significant substrate depletion before ACS Infectious Diseases pubs.acs.org/journal/aidcbc Article reaching the equilibrium between EI and EI*, leading to very small values of k 2 . Therefore, only the dissociation constant K I values from the first step were determined ( Figure 5 ). The inhibition constants (K I ) for calpain inhibitors II and XII with respect to MERS-CoV, SARS-CoV, and HCoV-OC43 M pro were 0.13 ± 0.012, 0.60 ± 0.041, and 0.23 ± 0.0088 μM and 1.32 ± 0.070, 0.14 ± 0.012, and 0.43 ± 0.015 μM, respectively; while the K I values for boceprevir with respect to SARS-CoV and HCoV-OC43 M pro were 1.43 ± 0.14 and 2.29 ± 0.19 μM, respectively. Taken together, the enzymatic kinetic results suggest that boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum enzymatic inhibition against SARS-CoV, MERS-CoV, and HCoV-OC43 M pro . Boceprevir, Calpain Inhibitors II and XII, and GC-376 Have Broad-Spectrum Antiviral Activity against Different CoVs. Given the binding and enzymatic inhibition of boceprevir, calpain inhibitors II and XII, and GC-376 against M pro from multiple CoVs, we expect these compounds will have broad-spectrum antiviral activity against CoVs in cell culture. For this, cellular antiviral assays were performed against multiple human CoVs including HCoV-229E, HCoV-NL63, HCoV-OC43, MERS-CoV, and SARS-CoV. Remdesivir was included as a positive control. It was found that all four compounds showed potent antiviral activity against all the CoVs tested in the viral cytopathic effect (CPE) assay in a dose-dependent manner (Table 1 and Figure S3 ). The 50% effective concentration EC 50 values of GC-376 range from 99 nM to 3.37 μM (Table 1 and Figure S3 ). Calpain inhibitors II and XII have comparable potency as GC-376, with EC 50 values in the range of 84 nM to 5.58 μM and 100 nM to 1.97 μM, respectively (Table 1 and Figure S3 ). In contrast, boceprevir showed moderate antiviral activity against all the CoVs tested and the EC 50 values were over 10 μM in most cases, except in the inhibition of SARS-CoV-2 (EC 50 = 1.31 ± 0.58 μM) ( Table 1 ). This result is in line with the weaker enzymatic inhibition of boceprevir against M pro s compared with GC-376, calpain inhibitors II and XII ( Figure 5E ). Nevertheless, the lack of a linear correlation between the enzymatic inhibition ( Figure 5E ) and cellular antiviral activity (Table 1 ) might arise from several factors including membrane permeability, drug efflux, metabolism, and protein binding. Furthermore, the dual mechanism of action of GC-376 and calpain inhibitors II and XII in inhibiting viral M pro and host cathepsin L further complicates the correlation.

To test whether boceprevir, calpain inhibitors II and XII, and GC-376 inhibit viral RNA synthesis, we performed the viral titer reduction assay using the RT-qPCR. HCoV-NL63 was chosen as a representative example and the viral nucleocapsid (N) gene expression level was detected in the absence or presence of different concentrations of compounds. Remdesivir was included as a positive control. All four compounds inhibited HCoV-NL63 viral N gene expression dose-dependently (Figure 7) , giving EC 50 values in the range of 0.96−19.86 μM (Figure 6 ), which were comparable to the EC 50 values determined in the antiviral CPE assays (Table 1) . Taken together, we have shown that boceprevir, calpain inhibitors II and XII, and GC-376 have broad-spectrum antiviral activity against CoVs.

Combination Therapy of Boceprevir, Calpain Inhibitors II and XII, and GC-376 with Remdesivir. The combination treatment potentials of boceprevir, calpain inhibitors II and XII, and GC-376 with remdesivir were explored using HCoV-OC43 antiviral CPE assay. Combination indices (CIs) versus the EC 50 values of compounds at different combination ratios were plotted as previously described. 35 The red line indicates additive effect; the right upper area above the red line indicates antagonism, while the left bottom area below the line indicates synergy. 35 In all combination scenarios, the combination indices at all the combination ratios fell on the red line (Figure 7) , suggesting that boceprevir, calpain inhibitors II and XII, and GC-376 displayed an additive antiviral effect with remdesivir in the combination therapy.

The COVID-19 pandemic that emerged in late December 2019 in China has had severe impacts on public health and the global economy. The high mortality rate and transmissibility of COVID-19 are unprecedented. There has been three outbreaks of highly pathogenic and lethal human coronaviruses within the past two decades, 2−4 and the current COVID-19 pandemic is a timely reminder of the urgent need for antivirals against CoVs. In this work, we report the broad-spectrum antiviral activity of our previously identified SARS-CoV-2 M pro inhibitors boceprevir, calpain inhibitors II and XII, and GC-376 against multiple CoVs including the highly pathogenic SARS-CoV, MERS-CoV, and human coronaviruses NL63, 229E, and OC43. Coupled with their antiviral activity against SARS-CoV-2 as reported earlier, this result suggests that these four compounds might be promising starting points for the further development of broad-spectrum antivirals against not only current coronaviruses but also possibly future emerging coronaviruses. Among the four compounds, GC-376 and calpain inhibitors II and XII had a dual mechanism of action by targeting both the viral M pro and host cathepsin L in Vero E6 cells. In this study, we provided additional evidence from pseudovirus neutralization assay to support this dual mechanism of action. We further demonstrated the additive antiviral effect of boceprevir, calpain inhibitors II and XII, and GC-376 with remdesivir in the combination therapy experiment. A recent study also showed the additive antiviral activity of GC-376 with remdesivir. 36 It is known that CoVs enter host cells through two distinct pathways: the early membrane fusion pathway and the late ACS Infectious Diseases pubs.acs.org/journal/aidcbc Article endosomal pathway. For the early membrane fusion pathway, the TMPRSS2 is responsible for the viral spike protein cleavage and activation. 37 In the late endosomal entry pathway, the cysteine protease cathepsin L mediates the cleavage of spike protein. 18 Several CoVs including SARS-CoV-2, SARS-CoV, MERS-CoV, HCoV-OC43, HCoV-229E, and HCoV-NL63 utilize cathepsin L for host cell entry, 18,38−42 which offers an opportunity to develop broad-spectrum antivirals by targeting the cathepsin L protease. Indeed, cathepsin L inhibitors have been actively explored for the development of coronavirus antivirals. 43−45 However, the translational potential of cathepsin L inhibitors remains to be validated due to their cell-type dependent antviral effect. 18−20 No animal model studies have been conducted in evaluating the in vivo antiviral efficacy of cathepsin L inhibitors against SARS-CoV-2 infection. Given the dual mechanism of action of GC-376 and calpain inhibitors II and XII in inhibiting both M pro and cathepsin L, there is a potential concern about cell-type dependent inhibition of these compounds. For this, we further tested the antiviral activity of these four compounds against SARS-CoV-2 in the TMPRSS2-expressing Caco-2 cells using viral yield reduction assay. It was found that all four compounds maintained potent antiviral activity, suggesting that the M pro inhibition might be the predominant driving factor for the cellular antiviral activity. Inhibiting cathepsin L might be beneficial in TMPRSS2-negative cells but might not be essential in preventing viral infection in the lung. Although M pro is relatively conserved among coronaviruses and picornaviruses, not all 3CL pro or 3C pro inhibitors have broad-spectrum antiviral activity. For example, the well-known 3CL pro inhibitor rupintrivir inhibits HCoV-229E with an EC 50 value of 0.3 μM; 46 however it did not inhibit the M pro from both SARS-CoV and SARS-CoV-2. 16, 46 This might be due to the slight differences of residues located at the active sites of M pro . Gratifyingly, we have shown in this study that boceprevir, calpain inhibitors II and XII, and GC-376 inhibited multiple M pro s from different members of the coronavirus family and had potent cellular antiviral activity against all the coronaviruses tested. Among these four compounds, calpain inhibitors II and XII, and GC-376 had single-digit to submicromolar antiviral potency with a high selectivity index, while boceprevir had moderate to weak antiviral activity. Therefore, boceprevir might not be a viable drug candidate for repurposing in clinical trials. Nevertheless, boceprevir represents a novel chemotype that warrants the further development as a SARS-CoV-2 antiviral candidate. The cocrystal structure of SARS-CoV-2 M pro with boceprevir has been solved and is expected to facilitate the structure−activity relationship studies. 36 It is important to highlight that the broad-spectrum antiviral activity of GC-376 and its analogs has been profiled. 46 In parallel to our study, GC-376 and calpain inhibitors II and XII were recently reported to inhibit HCoV-OC43 viral replication in cell culture, 47 which is consistent with our results. Moving forward, continuous optimization of boceprevir, calpain inhibitors II and XII, and GC-376 might yield clinical candidates with favorable pharmacokinetic properties and in vivo antiviral efficacy in animal models. Such studies are ongoing and will be reported when available.

Cell Lines and Viruses. The following reagents were obtained through BEI Resources, NIAID, NIH: human embryonic kidney cells (HEK-293T) expressing human angiotensin-converting enzyme 2, HEK-293T-hACE2 cell line, NR-52511; SARS-related coronavirus 2, Wuhan-Hu-1 spike-pseudotyped lentiviral kit, NR-52948. Human rhabdomyosarcoma (RD), Vero E6, Huh-7, HEK293T expressing ACE2 (ACE2/293T), and HCT-8 cell lines were maintained in Dulbecco's modified eagle's medium (DMEM); Caco-2 and MRC-5 cell lines were maintained in eagle's minimum essential medium (EMEM). Both media were supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-streptomycin antibiotics. Cells were kept at 37°C incubator in a 5% CO 2 atmosphere. The following reagents were obtained through BEI Resources, NIAID, NIH: human coronavirus, OC43, NR-52725; human coronavirus, NL63, NR-470. HCoV-OC43 was propagated in RD cells; HCoV-NL63 was propagated in MRC-5 cells. HCoV-229E was obtained from Dr. Bart Tarbet (Utah State University) and amplified in Huh-7 or MRC-5 cells. The Urbani strain of severe acute respiratory syndrome coronavirus (SARS-CoV) and the EMC/2012 strain Middle East respiratory syndrome coronavirus (MERS-CoV) were obtained from the Centers for Disease Control and Prevention. Vero 76 cells were obtained from the American Type Culture Collection.

Pseudovirus Neutralization Assay. Pseudotype HIV-1derived lentiviral particles bearing SARS-CoV-2 spike and a lentiviral backbone plasmid encoding luciferase as reporter was produced in HEK293 T cells engineered to express the SARS-CoV-2 receptor, ACE2 (ACE2/293 T cells), as previously described. 23 The pseudovirus was then used to infect Vero E6 cells in 96-well plates in the presence of DMSO or serial concentrations of E-64d, boceprevir, calpain inhibitors II and XII, and GC-376. At 48 hpi, cells from each well were lysed using the Bright-Glo Luciferase assay system (cat no.: E2610, Promega, Madison, WI, USA), and the cell lysates were transferred to 96-well Costar flat-bottom luminometer plates. The relative luciferase units (RLUs) in each well were detected using Cytation 5 cell imaging multi-mode reader (BioTek, Winooski, VT, USA).

Differential Scanning Fluorimetry (DSF). The binding of boceprevir, calpain inhibitors II and XII, and GC-376 to MERS-CoV, SARS-CoV, and HCoV-OC43 M pro s was monitored by differential scanning fluorimetry (DSF) using a Thermal Fisher QuantStudio 5 Real-Time PCR System as previously described 48 The progress curves were fitted as previously described. 16 Substrate depletion was observed when proteolytic reactions progress longer than 90 min, therefore only the first 90 min of the progress curves were used in the curve fitting. In this study, k 2 for boceprevir, calpain inhibitors II and XII, could not be accurately determined because of significant substrate depletion before the establishment of the equilibrium between EI and EI*, leading to very slow k 2 . In these cases, K I was determined with Morrison equation in Prism 8. SARS-CoV and MERS-CoV CPE Assays. Antiviral activities of test compounds were determined in nearly confluent cultures of Vero 76 cells. The assays were performed in 96-well Corning microplates. Cells were infected with approximately 30 cell culture infectious doses (CCID 50 ) of SARS-CoV or 40 CCID 50 of MERS-CoV. The plates were incubated at 37°C with 5% CO 2 and 50% effective concentrations (EC 50 ) were calculated based on virus-induced cytopathic effects (CPE) quantified by neutral red dye uptake after 4 days of incubation for SARS-CoV or 3 days of incubation for MERS-CoV. Three microwells at each concentration of compound were infected. Two uninfected microwells served as toxicity controls. Cells were stained for viability for 2 h with neutral red (0.11% final concentration). Excess dye was rinsed from the cells with phosphate-buffered saline (PBS). The absorbed dye was eluted from the cells with 0.1 mL of 50% Sorensen's citrate buffer (pH 4.2)/50% ethanol. Plates were read for optical density determination at 540 nm. Readings were converted to the percentage of the results for the uninfected control using an Excel spreadsheet developed for this purpose. EC 50 values were determined by plotting percent CPE versus log10 inhibitor concentration. Toxicity at each concentration was determined in uninfected wells in the same microplates by measuring dye uptake.

SARS-CoV-2 Viral Yield Reduction Assay in Caco-2 Cells. Caco-2 cells were maintained in MEM supplemented with 10% FBS. For antiviral assays, FBS reduced to 2% and the medium was supplemented with 50 μg mL −1 gentamicin. The test compounds were stored as 50 mM stocks in DMSO. The test compounds were prepared at eight serial half-log 10 concentrations beginning at a high concentration of 100 μM.

Growth media was removed from the cells and the test compounds were applied to wells at 2× concentration. Virus at 400 CCID 50 (50% cell culture infectious dose) was added to the wells designated for virus infection corresponding to a multiplicity of infection (MOI) of 0.01. Plates were incubated at 37°C with 5% CO 2 for 72 h. A sample of supernatant is taken from each infected well (three replicate wells pooled) and tested for virus titer determination.

Cytotoxicity was determined by the uptake of neutral red dye. Briefly, plates were stained with 0.011% neutral red for approximately two hours at 37°C in a 5% CO 2 incubator. The neutral red medium was removed by aspiration, and the cells were rinsed 1× with phosphate buffered solution (PBS) to remove residual dye. The incorporated neutral red was eluted with 50% Sorensen's citrate buffer/50% ethanol for at least 30 min. The dye content in each well is quantified using a spectrophotometer at 540 nm wavelength. The dye content in each set of wells is converted to a percentage of dye present in untreated control wells using a Microsoft Excel computerbased spreadsheet and normalized based on the virus control. The 50% cytotoxic (CC 50 , cell-inhibitory) concentrations are then calculated by regression analysis.

Titration of the viral samples (collected as described in the paragraph above) was performed by end point dilution. 50 Serial 1/10 dilutions of virus were prepared and plated into four replicate wells containing fresh cell monolayers of Vero 76 cells. Plates were then incubated, and cells are scored for the presence or absence of virus after distinct CPE is observed. The CCID 50 was calculated using the Reed−Muench method. 50 The 90% (one log 10 ) effective concentration (EC 90 ) is calculated by regression analysis by plotting the log 10 of the inhibitor concentration versus log 10 of virus produced at each concentration. The quotient of CC 50 divided by EC 90 gives the selectivity index (SI) value.

HCoV-OC43, HCoV-229E, and HCoV-NL63 CPE Assays. Antiviral activities of boceprevir, calpain inhibitors II and XII, and GC-376 against HCoV-229E, HCoV-NL63, and HCoV-OC43 were tested in CPE assays as previously described 51 with minor modifications. Briefly, cell cultures near confluency in 96-well plates were infected with 100 μL of viruses at desired dilutions and incubated for 1 h. Unabsorbed virus was removed and different concentrations of testing compounds (0, 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100 μM) were added. Remdesivir was included as a positive control. The plates were incubated for another 3 to 5 days when a significant cytopathic effect was observed in the wells without compound (virus only). Cells were stained with 0.1 mg/mL neutral red for 2 h and excess dye was rinsed from the cells with PBS. The absorbed dye was dissolved with a buffer containing 50% ethanol and 1% glacial acetic acid. Plates were read for optical density determination at 540 nm. Readings were normalized with uninfected controls. EC 50 values were determined by plotting percent CPE versus log 10 compound concentrations from best-fit dose response curves with variable slope in Prism 8. Toxicity at each concentration was determined in uninfected cells in the same microplates by measuring neutral red dye uptake.

RNA Extraction and Real-Time PCR. RNA extraction and RT-PCR were performed as previously described. 52 Total RNA was extracted from HCoV-NL63 virus infected Caco-2 cells at an MOI of 0.05 at 48 h post infection using TRIzol reagents (Thermo Fisher Scientific). A 2.0 μg portion of total RNA was used to synthesize the first strand cDNA of viral ACS Infectious Diseases pubs.acs.org/journal/aidcbc Article RNA and host RNA using SuperScript III reverse transcriptase (Thermo Fisher Scientific) and Random Hexamer primer. Viral RNA was amplified on a Thermal Fisher QuantStudio 5 real-time PCR system (Thermo Fisher Scientific) using FastStart Universal SYBR Green Master mix (carboxy-Xrhodamine; Roche) and HCoV-NL63 N gene-specific primers (forward 5′-CTGTTACTTTGGCTTTAAAGAACTTAGG-3′; reverse 5′-CTCACTATCAAAGAATAACGCAGCCTG-3′). GAPDH was also amplified to serve as a control using human GAPDH-specific primers (GAPDH-F 5′-ACACCC-ACTCCTCCACCTTTG-3′; GAPDH-R 5′-CACCACCCTG-TTGCTGTAGCC-3′). The amplification conditions were as follows: 95°C for 10 min; 40 cycles of 15 s at 95°C and 60 s at 60°C. Melting curve analysis was performed to verify the specificity of each amplification. All experiments were repeated three times independently. Combination Therapy. Boceprevir, calpain inhibitors II and XII, and GC-376 was mixed with remdesivir at combination ratios of 8:1, 4:1, 2:1, 1:1, 1:2, 1:4, and 1:8 separately. The mixture of each compound with remdesivir at each combination ratio was serially diluted into seven different concentrations and applied in HCoV-OC43 CPE assay to determine EC 50 of each compound and remdesivir in the combination ratio. A combination indices (CIs) plot was used to depict the EC 50 values of each compound and remdesivir at different combination ratios. The red line indicates the additive effect; above the red line indicates the antagonism, while below the red line indicates the synergy. 35 ■ ASSOCIATED CONTENT

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsinfecdis.0c00761.

Sequence alignment of coronaviruses ( Figure S1 ); amino acid conservation among HCoVs (Table S1) ; enzymatic kinetic studies of HCoV M pro s in the presence or absence of inhibitors ( Figure S2 ); cellular antiviral activity of GC-376, calpain inhibitors II and XII, and boceprevir against a panel of coronaviruses ( Figure S3 ) (PDF)

Characteristics of SARS-CoV-2 and COVID-19

From SARS to MERS: 10 years of research on highly pathogenic human coronaviruses

Middle East respiratory syndrome

The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health -The latest 2019 novel coronavirus outbreak in Wuhan

Epidemiological and clinical features of human coronavirus infections among different subsets of patients. Influenza Other Respir

Identification of a new human coronavirus

Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia

Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses

Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs

Comparative genome analysis of ACS Infectious Diseases pubs

SARS-CoV-2) from different geographical locations and the effect of mutations on major target proteins: An in silico insight

Profiling of substrate specificities of 3C-like proteases from group 1, 2a, 2b, and 3 coronaviruses

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors

The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor

Structure of Main Protease from Human Coronavirus NL63: Insights for Wide Spectrum Anti-Coronavirus Drug Design

Structure of the main protease from a global infectious human coronavirus, HCoV-HKU1

Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against M(pro) and cathepsin L

Cell entry mechanisms of SARS-CoV-2

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Proteases as a Therapeutic Strategy for COVID-19

and TMPRSS4 facilitate trypsin-independent spread of influenza virus in Caco-2 cells

Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells

Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays

Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2

The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate co-receptor

Inhibitory effect of di-and tripeptidyl aldehydes on calpains and cathepsins

Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis

Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations

Proteomics of SARS-CoV-2-infected host cells reveals therapy targets

Robust and persistent SARS-CoV-2 infection in the human intestinal brush border expressing cells

The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability

Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir

Pharmacological Characterization of the Mechanism of Action of R523062, a Promising Antiviral for Enterovirus D68

TMPRSS2 activates the human coronavirus 229E for cathepsin-independent host cell entry and is expressed in viral target cells in the respiratory epithelium

Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide

ACS Infect. Dis. 2021

Protease-mediated entry via the endosome of human coronavirus 229E

Proteolytic processing of Middle East respiratory syndrome coronavirus spikes expands virus tropism

Entry of Human Coronavirus NL63 into the Cell

Early events during human coronavirus OC43 entry to the cell

Inhibitors of cathepsin L prevent severe acute respiratory syndrome coronavirus entry

SARS-CoV-2 Entry Inhibitors: Small Molecules and Peptides Targeting Virus or Host Cells

Cathepsin Lselective inhibitors: A potentially promising treatment for COVID-19 patients

Broadspectrum antivirals against 3C or 3C-like proteases of picornaviruses, noroviruses, and coronaviruses

Evaluation of SARS-CoV-2 3C-like protease inhibitors using self-assembled monolayer desorption ionization mass spectrometry

Validating Enterovirus D68− 2A(pro) as an Antiviral Drug Target and the Discovery of Telaprevir as a Potent D68−2A(pro) Inhibitor

Dipyridamole, chloroquine, montelukast sodium, candesartan, oxytetracycline, and atazanavir are not SARS-CoV-2 main protease inhibitors

Discovery of dapivirine, a nonnucleoside HIV-1 reverse transcriptase inhibitor, as a broad-spectrum antiviral against both influenza A and B viruses

Exploring Ugi-Azide Four-Component Reaction Products for Broad-Spectrum Influenza Antivirals with a High Genetic Barrier to Drug Resistance

ACS Infect. Dis. 2021